| Interventions |
Group 1: LASIK in patients with diabetes mellitus: To investigate the efficacy, safety, and predictability of refractive outcomes in terms of CDVA and UDVA, respectively, pre- and postoperatively (2 weeks before and 3 months after surgery). In addition, we analyze postoperative outcomes, including complication and re-treatment rates. Group 2: LASIK in patients taking antidepressants: To investigate the efficacy, safety, and predictability of refractive outcomes in terms of CDVA and UDVA, respectively, pre- and postoperatively (2 weeks before and 3 months after surgery). In addition, we analyze postoperative outcomes, including complication and re-treatment rates. Group 3: LASIK in patients with ankylosing spondylitis: To investigate the efficacy, safety, and predictability of refractive outcomes in terms of CDVA and UDVA, respectively, pre- and postoperatively (2 weeks before and 3 months after surgery). In addition, we analyze postoperative outcomes, including complication and re-treatment rates. Group 4: LASIK in patients with inflammatory bowel disease: To investigate the efficacy, safety, and predictability of refractive outcomes in terms of CDVA and UDVA, respectively, pre- and postoperatively (2 weeks before and 3 months after surgery). In addition, we analyze postoperative outcomes, including complication and re-treatment rates. Group 5: LASIK in patients with hay fever: To investigate the efficacy, safety, and predictability of refractive outcomes in terms of CDVA and UDVA, respectively, pre- and postoperatively (2 weeks before and 3 months after surgery). In addition, we analyze postoperative outcomes, including complication and re-treatment rates. Group 6: LASIK in patients with atopic dermatitis: To investigate the efficacy, safety, and |